skip to main content

Mesothelioma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerMesotheliomaSCE Medical Oncology

A fit patient with untreated, unresectable biphasic malignant pleural mesothelioma has ECOG performance status 1 and no autoimmune contraindication. Which first-line systemic treatment is NICE recommended irrespective of epithelioid versus non-epithelioid histology?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Nivolumab plus ipilimumab as first-line dual checkpoint inhibition under TA818

TA818 recommends nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma in adults with ECOG 0 or 1, and the recommendation applies across histological subtypes. Pemetrexed-platinum remains clinically relevant but is not the unique answer to the appraisal-specific question. Nivolumab is not sequenced as monotherapy followed by ipilimumab, and pembrolizumab-platinum-pemetrexed did not have a routine positive NICE appraisal in this setting.

Reference: NICE TA818 nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (Published August 2022): https://www.nice.org.uk/guidance/TA818/chapter/1-Recommendations